| | SNPs | Country
RA/HC | Results | Reference |
| | PADI4_89-105 | Japan
(830/736) | PADI4_92, 94, 95, 97, 99, 100, 101 and 104
(P = 0.0000084–0.00051) |
Suzuki et al. 2003 [9] | | PADI4_89, 90, 92, 104 | UK
(839/481) | Susceptibility haplotype more frequent in RA patients (32.3 versus 29.6) without significance
(P = 0.79) |
Barton et al. 2004 [27] | | PADI4_92, 96 and 102 | France
(100 families) | No significant associations |
Caponi et al. 2005 [28] | | PADI4_92, 94, 97, 99, 100, 103 and 104 | England
(111/111) | PADI4_100 and 103 (P = 0.03). Increase in mRNA expression of PADI4 in PBM from RA versus C |
Harney et al. 2005 [12] | | PADI4_94, 102 and 104 | Japan
(1170/926) | PADI4_94, 102, and 104
(P = 0.0008–0.010) |
Ikari et al. 2005 [26] | | PADI4_94 and 104 | Spain
(354/498) | No significant associations |
Martinez et al. 2005 [29] | | PADI4_94 | Sweden and North America | Association with RA
(P = 0.02) |
Plenge et al. 2005 [55] | | PADI4_89, 90, 92 and 104 | Korea
(545/392) | Strong association of RA with susceptibility haplotype
(P = 1.0 × 10−4) |
Kang et al. 2006 [47] | | PADI4_89, 90, 92, 94, 95, 96 and 104 | Germany
(102/102) | PADI4_89, 90, and 94
(P = 0.04) |
Hoppe et al. 2006 [11] | | PADI4_89 and 90 | France
(405/275) | Association with RA
(P = 0.03 and 0.003) |
Gandjbakhch et al. 2009 [48] |
|
|
